Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL) Share News

234567891011

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

8th Apr 2014 11:05

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6 Read More

ValiRx Anti-Cancer Compound To Undergo Further Study

1st Apr 2014 09:22

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea Read More

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

19th Mar 2014 12:10

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2 Read More

ValiRx Biomarket Receives European Patent Approval

20th Feb 2014 11:10

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in Read More

ValiRx Sells Shares In VolitionRx For USD601,578

31st Jan 2014 13:03

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c Read More

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

27th Dec 2013 08:27

Read More

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

28th Nov 2013 12:27

Read More

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

28th Nov 2013 08:22

Read More

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

15th Nov 2013 12:39

Read More

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

15th Nov 2013 12:37

Read More

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

15th Nov 2013 10:28

Read More

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

15th Nov 2013 07:53

Read More

ValiRx Anti-Cancer Treatment Advances To Phase 2 Of Clinical Trial

24th Oct 2013 15:48

Read More

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

3rd Oct 2013 11:39

Read More

ValiRx Cancer Treatment Files Escalation Study

3rd Oct 2013 08:08

Read More

ValiRx Losses Widen But Says Compounds Progressing In Trials

5th Sep 2013 09:20

Read More

234567891011
FTSE 100 Latest
Value8,809.74
Change53.53